Sign In
Buy RVTY
$101.07
+0.680 (+0.677%)
At Close: Jun 03, 2026
Revvity Board Declares Quarterly Dividend
04:05pm, Thursday, 24'th Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 8, 2
Earnings Preview: Revvity (RVTY) Q1 Earnings Expected to Decline
11:05am, Monday, 21'st Apr 2025
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revvity to Hold Earnings Call on Monday, April 28, 2025
08:00am, Thursday, 03'rd Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its first quarter 2025 financial results prior to market open on Monday, April 28, 2025. The Company w
Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
08:51am, Wednesday, 02'nd Apr 2025
RVTY's strong product portfolio raises optimism about the stock.
Revvity Signals Software Unveils Unified Data Platform to Accelerate Drug Discovery
08:00am, Wednesday, 02'nd Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. announced that its software and informatics division, Revvity Signals Software, will launch its Signals One™, a unified software platform evolve
Revvity Secures FDA Approval for Improved Automated Latent Tuberculosis Test
08:00am, Wednesday, 02'nd Apr 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT�
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
01:55pm, Friday, 21'st Mar 2025
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
01:00pm, Thursday, 20'th Mar 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
12:30pm, Thursday, 20'th Feb 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rig
Revvity to Present at Upcoming Investor Conferences
08:00am, Thursday, 20'th Feb 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Confe
Molecular Infectious Disease Testing Market to Hit USD 17.78 Billion by 2029 with 13.7% CAGR | MarketsandMarkets™.
10:05am, Thursday, 13'th Feb 2025
DELRAY BEACH, Fla., Feb. 13, 2025 /PRNewswire/ -- The global Molecular Infectious Disease Testing market, valued at US$8.49 billion in 2023, is forecasted to grow at a robust CAGR of 13.7%, reaching U
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
02:15pm, Friday, 31'st Jan 2025
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say
10:35am, Friday, 31'st Jan 2025
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compar
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript
09:34am, Friday, 31'st Jan 2025
Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Ch
Revvity (RVTY) Surpasses Q4 Earnings Estimates
08:11am, Friday, 31'st Jan 2025
Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago.
